RYAN ARTHUR F 4
4 · REGENERON PHARMACEUTICALS, INC. · Filed Feb 11, 2026
Research Summary
AI-generated summary of this filing
Regeneron (REGN) Director Ryan Arthur F Sells Shares
What Happened
- Ryan Arthur F, a director of Regeneron Pharmaceuticals (REGN), sold 100 shares in multiple open-market transactions on February 9, 2026, realizing approximately $77,854 total. Individual trade prices ranged roughly from $775.63 to $787.82 per share (grouped volume‑weighted averages reported for several blocks).
Key Details
- Transaction date: February 9, 2026; Form 4 filed February 11, 2026 (timely).
- Transaction type/code: Open-market sales (S).
- Shares sold: 100 total across multiple trades; total proceeds ≈ $77,854.
- Price range: about $775.63 to $787.82 per share; several VWAPs reported for blocks of 10, 57, 12, 5, 5 and 3 shares (see footnotes F2–F7 in the filing).
- Plan/footnote: Dispositions were made pursuant to a Rule 10b5-1(c) trading plan adopted Oct 31, 2025 (footnote F1).
- Shares owned after transaction: not specified in the summary provided; consult the full filing for post-transaction holdings.
Context
- These were outright sales under a pre-arranged 10b5-1 plan, which indicates the trades were planned in advance and are generally considered routine rather than a contemporaneous signal of insider sentiment. Sales (S) are less informative about future prospects than purchases, which can indicate increased insider confidence.
Insider Transaction Report
Form 4
RYAN ARTHUR F
Director
Transactions
- Sale
Common Stock
[F1]2026-02-09$775.63/sh−1$776→ 17,902 total - Sale
Common Stock
[F1][F2]2026-02-09$776.59/sh−10$7,766→ 17,892 total - Sale
Common Stock
[F1][F3]2026-02-09$777.56/sh−57$44,321→ 17,835 total - Sale
Common Stock
[F1][F4]2026-02-09$778.53/sh−12$9,342→ 17,823 total - Sale
Common Stock
[F1][F5]2026-02-09$779.41/sh−5$3,897→ 17,818 total - Sale
Common Stock
[F1]2026-02-09$780.09/sh−1$780→ 17,817 total - Sale
Common Stock
[F1][F6]2026-02-09$781.48/sh−5$3,907→ 17,812 total - Sale
Common Stock
[F1]2026-02-09$782.53/sh−1$783→ 17,811 total - Sale
Common Stock
[F1][F7]2026-02-09$783.34/sh−3$2,350→ 17,808 total - Sale
Common Stock
[F1]2026-02-09$784.59/sh−1$785→ 17,807 total - Sale
Common Stock
[F1]2026-02-09$785.71/sh−1$786→ 17,806 total - Sale
Common Stock
[F1]2026-02-09$786.29/sh−2$1,573→ 17,804 total - Sale
Common Stock
[F1]2026-02-09$787.82/sh−1$788→ 17,803 total
Footnotes (7)
- [F1]Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025.
- [F2]Represents volume-weighted average price of sales of 10 shares of Company stock on February 9, 2026 at prices ranging from $776.04 to $776.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price.
- [F3]Represents volume-weighted average price of sales of 57 shares of Company stock on February 9, 2026 at prices ranging from $777.02 to $777.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price.
- [F4]Represents volume-weighted average price of sales of 12 shares of Company stock on February 9, 2026 at prices ranging from $778.11 to $778.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price.
- [F5]Represents volume-weighted average price of sales of 5 shares of Company stock on February 9, 2026 at prices ranging from $779.13 to $779.76. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price.
- [F6]Represents volume-weighted average price of sales of 5 shares of Company stock on February 9, 2026 at prices ranging from $781.05 to $781.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price.
- [F7]Represents volume-weighted average price of sales of 3 shares of Company stock on February 9, 2026 at prices ranging from $783.20 to $783.61. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price.
Signature
/s/ Arthur F. Ryan|2026-02-11